secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0001104659-23-054807
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa raises ARCALYST FY2023 guidance; Q1 revenue $48.3M, net loss narrows
----------------------------------------------------------------------------

- ARCALYST Q1 net product revenue $42.7M; FY2023 guidance raised to $200-215M (~69% YoY growth at midpoint).
- Net loss improved to $12.3M from $25.2M YoY; total revenue $48.3M vs $32.2M.
- Cash & short-term investments $187.5M, no debt; cash runway now expected into at least 2026.
- Final cohort of KPL-404 Phase 2 RA trial enrolling; data expected 1H 2024.
- Over 1,000 prescribers written ARCALYST scripts since launch; payer approval rate >90%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465923054807/0001104659-23-054807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465923054807/tm2314130d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-054807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer